- Androgen deprivation therapy — one of the most common treatments for
prostate cancer — may increase the risk of death from heart disease in
patients over age 65, according to a new study by researchers at
Dana-Farber Cancer Institute, Brigham and Women's Hospital and other
- Researchers at Dana-Farber Cancer Institute have found a
previously unknown molecular pathway in mice that spurs the growth of
new blood vessels when body parts are jeopardized by poor circulation.
- The use of monoclonal antibodies to activate an immune-system response
to abnormal cells resulted in a significant increase in survival time in
patients with metastatic melanoma, report Dana-Farber researchers.
Tags: ImmuneSystem, Melanoma, TranslationalResearch
- Combination of cell-killing drug and monoclonal antibody slowed or
halted tumor growth in almost half a group of patients whose cancers had
become resistant to standard treatments.
Tags: Antibody, BreastCancer
- Elevated levels of anxiety may cause women with ductal carcinoma in situ (DCIS), the most common form of non-invasive breast cancer, to overestimate their risk of recurrence or dying from breast cancer, suggests a study led by Dana-Farber researchers.
- Two Dana-Farber researchers have been given an award for young investigators who are advancing the field of cancer research. Scott Armstrong, MD, PhD, is being recognized for achievements in cancer stem cell research and genomics; Kornelia Polyak, MD, PhD, for her pioneering discoveries in breast tissue.
Tags: BasicResearch, Honors, TranslationalResearch
- The reduced risk of colorectal cancer associated with taking aspirin or
NSAIDs may be confined to individuals already at risk because of
elevations in a particular inflammatory factor in the blood, researchers
at Dana-Farber Cancer Institute and Massachusetts General Hospital
Tags: ColonCancer, Prevention
- Baruj Benacerraf, MD, who earned a 1980 Nobel Prize in Physiology or Medicine for his groundbreaking research in immunology and led Dana-Farber for a number of years, died in Boston on Aug. 2 at the age of 90.
- Dana-Farber chief medical officer Lawrence N. Shulman, MD, will oversee design of a new cancer care model in Bermuda.
Showing 21-30 of 442 items